Monte Rosa Therapeutics (GLUE) Cash from Investing Activities (2020 - 2026)

Monte Rosa Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$261.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 160.4% year-over-year to -$261.0 million; the TTM figure through Mar 2026 stood at -$262.6 million (down 69.93% YoY), while the FY2025 annual figure was -$101.8 million, down 129.09% from the prior year.
• Cash from Investing Activities was -$261.0 million for Q1 2026 at Monte Rosa Therapeutics, down from -$65.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $38.1 million in Q3 2025 to a low of -$261.0 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$31.6 million across 5 years, with a median of $9.9 million in 2024.
• Biggest YoY gain for Cash from Investing Activities was 1846.98% in 2022; the steepest drop was 8042.53% in 2022.
• A 5-year view of Cash from Investing Activities shows it stood at -$53.9 million in 2022, then surged by 126.51% to $14.3 million in 2023, then tumbled by 316.1% to -$30.9 million in 2024, then sank by 110.6% to -$65.1 million in 2025, then tumbled by 301.13% to -$261.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$261.0 million (Q1 2026), -$65.1 million (Q4 2025), and $38.1 million (Q3 2025), per Business Quant data.